PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Get Free Report) insider Deepika Jalota sold 4,104 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $6.62, for a total transaction of $27,168.48. Following the completion of the sale, the insider now owns 29,946 shares in the company, valued at $198,242.52. The transaction was disclosed in a filing with the SEC, which is available through this link.
PMV Pharmaceuticals Stock Performance
NASDAQ PMVP opened at $6.21 on Tuesday. The stock’s 50-day simple moving average is $7.00 and its two-hundred day simple moving average is $5.94. PMV Pharmaceuticals, Inc. has a twelve month low of $3.84 and a twelve month high of $13.02.
PMV Pharmaceuticals (NASDAQ:PMVP – Get Free Report) last issued its quarterly earnings results on Wednesday, August 9th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.09. Research analysts predict that PMV Pharmaceuticals, Inc. will post -1.67 EPS for the current year.
Wall Street Analysts Forecast Growth
Hedge Funds Weigh In On PMV Pharmaceuticals
Several institutional investors and hedge funds have recently bought and sold shares of PMVP. State Street Corp increased its stake in shares of PMV Pharmaceuticals by 101.6% in the second quarter. State Street Corp now owns 5,171,490 shares of the company’s stock worth $73,694,000 after buying an additional 2,605,945 shares during the period. BlackRock Inc. boosted its holdings in shares of PMV Pharmaceuticals by 16.1% during the second quarter. BlackRock Inc. now owns 4,677,028 shares of the company’s stock worth $29,278,000 after purchasing an additional 646,859 shares during the period. JPMorgan Chase & Co. grew its stake in shares of PMV Pharmaceuticals by 1.8% in the second quarter. JPMorgan Chase & Co. now owns 4,075,504 shares of the company’s stock worth $25,513,000 after purchasing an additional 72,620 shares during the last quarter. Vanguard Group Inc. raised its position in PMV Pharmaceuticals by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,433,965 shares of the company’s stock valued at $40,865,000 after purchasing an additional 78,001 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in PMV Pharmaceuticals by 114.0% in the 4th quarter. Bank of America Corp DE now owns 1,015,216 shares of the company’s stock worth $8,832,000 after buying an additional 540,845 shares during the period.
About PMV Pharmaceuticals
PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.
- Five stocks we like better than PMV Pharmaceuticals
- Health Care Stocks Explained: Why You Might Want to Invest
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- 5 Reasons Mullen Automotive is About to Turn a Corner
- How Investors Can Find the Best Cheap Dividend Stocks
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.